Clinical Trials Logo

Immunogenicity clinical trials

View clinical trials related to Immunogenicity.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05911087 Not yet recruiting - Safety Clinical Trials

A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2

Start date: June 20, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Primary Immunogenicity Objective:Cohort 1: GMTs of SARS-CoV-2 Omicron and related strain neutralizing antibody levels for SWIM816.Cohort 2: To demonstrate the non- inferiority of neutralizing antibody response in terms of geometric mean titers (GMT) of COVID-19 mRNA vaccine(SWIM816) compare with mRNA COVID-19 vaccine(Pfizer Bivalent vaccine) 14 days post dose. Primary Safety Objective:To assess the reactogenicity and safety of a booster dose in a heterologous vaccination regimen in subjects previously immunized with 2/3 doses of COVID-19 vaccine with or without previously diagnosed with COVID-19. Secondary Immunogenicity Objectives:To describe the neutralizing antibody response at D29, D91 and D181.To describe binding antibody profile at D01, D15, D29, D91 and D181 of each study group. Secondary Safety Objective:To assess the reactogenicity and safety of third or fourth booster dose in a heterologous vaccination regimen in subjects previously immunized with 2/3 COVID-19 vaccine doses. Exploratory Objective:1.Documented confirmed SARS-CoV-2 symptomatic infection;2.Todemonstrate the cellular immune response profile at study group (30 subjects per each group for cellular immune testing).